Art. -Nr.: HY-B1415

Clofibric acid

(Synonyms: Chlorofibrinic acid)

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

Clofibric acid (Chlorofibrinic acid) is an orally active PPARα agonist. Clofibric acid inhibits the fimbriation of Escherichia coli. Clofibric acid increases SOD activity. Clofibric acid lowers blood lipids and prevents experimental pyelonephritis. Clofibric acid has anticancer activity against ovarian cancer. Clofibric acid is also a herbicide. Clofibric acid is used in ovarian cancer, liver cancer, obesity, and urinary tract infection research.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.92%
CAS. Nr.: 882-09-7
Formel: C₁₀H₁₁ClO₃
Molecular Weight:214.65

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Clofibric acid Chemical Structure

CAS. Nr.: 882-09-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

PPARα^[1]

Alle PPAR Isoform-spezifische Produkte anzeigen :

Alle Ligands for E3 Ligase Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
CV-1	EC₅₀	>300 μM Compound: 1b	Compound was tested for agonist activity on human Peroxisome proliferator activated receptor gamma-Gal4 chimeric receptor in transfected CV-1 cells Compound was tested for agonist activity on human Peroxisome proliferator activated receptor gamma-Gal4 chimeric receptor in transfected CV-1 cells	[PMID: 10508427]
CV-1	EC₅₀	>300 μM Compound: 1b	Compound was tested for its agonist activity against murine Peroxisome proliferator activated receptor gamma-Gal4 chimeric receptor in transfected CV-1 cells Compound was tested for its agonist activity against murine Peroxisome proliferator activated receptor gamma-Gal4 chimeric receptor in transfected CV-1 cells	[PMID: 10508427]
CV-1	EC₅₀	50 μM Compound: 1b	Compound was tested for its agonist activity against murine Peroxisome proliferator activated receptor alpha-Gal4 chimeric receptor transfected CV-1 cells Compound was tested for its agonist activity against murine Peroxisome proliferator activated receptor alpha-Gal4 chimeric receptor transfected CV-1 cells	[PMID: 10508427]
CV-1	EC₅₀	51 μM Compound: 1b	In vitro transcriptional activation of peroxisome proliferator activated alpha-receptor (PPAR) expressed in CV-1 cells In vitro transcriptional activation of peroxisome proliferator activated alpha-receptor (PPAR) expressed in CV-1 cells	[PMID: 8576907]
CV-1	EC₅₀	55 μM Compound: 1b	Compound was tested for agonist activity on human Peroxisome proliferator activated receptor alpha-Gal4 chimeric receptor in transfected CV-1 cells Compound was tested for agonist activity on human Peroxisome proliferator activated receptor alpha-Gal4 chimeric receptor in transfected CV-1 cells	[PMID: 10508427]
CV-1	EC₅₀	600 μM Compound: 1b	In vitro transcriptional activation of Peroxisome proliferator activated receptor gamma (PPAR) expressed in CV-1 cells In vitro transcriptional activation of Peroxisome proliferator activated receptor gamma (PPAR) expressed in CV-1 cells	[PMID: 8576907]
HEK293	EC₅₀	55 μM Compound: 2	Transactivation of human GAL4-fused PPARalpha ligand binding domain transfected in HEK293 cells after 18 hrs by dual luciferase reporter gene assay Transactivation of human GAL4-fused PPARalpha ligand binding domain transfected in HEK293 cells after 18 hrs by dual luciferase reporter gene assay	[PMID: 23102891]
HEK293	EC₅₀	55 μM Compound: 7	Agonist activity at human PPARalpha expressed in HEK293 cells assessed as receptor transactivation at by luciferase reporter gene assay Agonist activity at human PPARalpha expressed in HEK293 cells assessed as receptor transactivation at by luciferase reporter gene assay	[PMID: 19791744]
HEK293	EC₅₀	55 μM Compound: Clofibric acid	Agonist activity at PPARalpha ligand binding domain expressed in HEK293 cells co-expressing GAL4 after 18 hrs by dual-luciferase activity based transactivation assay Agonist activity at PPARalpha ligand binding domain expressed in HEK293 cells co-expressing GAL4 after 18 hrs by dual-luciferase activity based transactivation assay	[PMID: 21742490]
HEK293-A	EC₅₀	55 μM Compound: 7	Transactivation of PPARalpha expressed in HEK293A cells co-expressing GAL4 after 16 to 18 hrs by luciferase reporter gene assay Transactivation of PPARalpha expressed in HEK293A cells co-expressing GAL4 after 16 to 18 hrs by luciferase reporter gene assay	[PMID: 23137448]
HepG2	EC₅₀	309 μM Compound: Clofibric acid	Effective concentration against human PPARgamma expressed in HepG2 cells Effective concentration against human PPARgamma expressed in HepG2 cells	[PMID: 16107150]
HepG2	EC₅₀	39.6 μM Compound: Clofibric acid	Effective concentration against human PPARalpha expressed in HepG2 cells Effective concentration against human PPARalpha expressed in HepG2 cells	[PMID: 16107150]
HepG2	EC₅₀	50 μM Compound: Clofibric acid	Transactivation of GAL4-tagged human PPARalpha LBD expressed in human HepG2 cells at 100 nM to 100 uM incubated for 20 to 22 hrs by luciferase reporter gene assay Transactivation of GAL4-tagged human PPARalpha LBD expressed in human HepG2 cells at 100 nM to 100 uM incubated for 20 to 22 hrs by luciferase reporter gene assay	[PMID: 30996794]

In Vitro

Clofibric acid (0-500 μM; 72 h) inhibits the proliferation of OVCAR-3 and DISS cells dose-dependently^[1].
Clofibric acid (0.25-0.75 mM; 5 days) increases total SOD and MnSOD activities, as well as the enzyme apoprotein and MnSOD mRNA levels in HepG2 cells^[2].
Clofibric acid (10-1000 μM; 72 h after 24-h pre-incubation) increases peroxisomal β-oxidation, the relative number of peroxisomes and the mean size of peroxisomes in primary cultures of rat hepatocytes^[3].
Clofibric acid (0.1-5 mM) decreases the growth rate of uropathogenic E. coli T149 in urine^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Clofibric acid (9000 ppm in diet; p.o.; daily; until the end of the study) significantly suppresses the growth of OVCAR-3 tumors xenotransplanted s.c. in nude mice and significantly prolongs the survival of mice with malignant ascites derived from DISS cells^[1].
Clofibric acid (200 mg/kg body weight; s.c.; daily; from 6-36 weeks of age) significantly lowers fasted serum cholesterol levels in obese Zucker rats, and has various effects on the weights and lipid/cholesterol levels of different organs^[4].
Clofibric acid (29 mg/kg bw; p.o.; daily) abolishes renal infection in mice with ascending urinary tract infection caused by E. coli and does not produce adverse effects on the renal parenchyma^[5].
Clofibric acid (100 mg/kg; i.p.; single) attenuates Carbon tetrachloride (HY-Y0298)-induced necrosis in rats^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 882-09-7
Appearance Solid
Molecular Weight 214.65
Formel C₁₀H₁₁ClO₃
Color White to off-white
SMILES

CC(C)(OC1=CC=C(Cl)C=C1)C(O)=O
Synonyms

Chlorofibrinic acid
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (1)

All

Sort by:

Journal Impact Factor

Cell Press Blue

2026 Apr 22.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 100 mg/mL (465.87 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 1 mg/mL (4.66 mM; ultrasonic and warming and heat to 80°C)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.6587 mL

23.2937 mL

46.5875 mL

5 mM

0.9317 mL

4.6587 mL

9.3175 mL

10 mM

0.4659 mL

2.3294 mL

4.6587 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (11.65 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (11.65 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (11.65 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (300 KB)
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Yokoyama Y, et al. Clofibric acid, a peroxisome proliferator-activated receptor alpha ligand, inhibits growth of human ovarian cancer. Mol Cancer Ther. 2007 Apr;6(4):1379-86. [Content Brief]

[2]. Bécuwe P, et al. Effects of the peroxisome proliferator clofibric acid on superoxide dismutase expression in the human HepG2 hepatoma cell line. Biochem Pharmacol. 1999 Sep 15;58(6):1025-33. [Content Brief]

[3]. Blaauboer B J, et al. The effect of beclobric acid and clofibric acid on peroxisomal β-oxidation and peroxisome proliferation in primary cultures of rat, monkey and human hepatocytes. Biochemical Pharmacology, 1990, 40(3): 521-528.

[4]. Cleary MP, et al. Effect of long-term clofibric acid treatment on serum and tissue lipid and cholesterol levels in obese Zucker rats. Atherosclerosis. 1987 Jul;66(1-2):107-12. [Content Brief]

[5]. Balagué CE, et al. Clofibric and ethacrynic acids prevent experimental pyelonephritis by Escherichia coli in mice. FEMS Immunol Med Microbiol. 2004 Nov 1;42(3):313-9. [Content Brief]

[6]. Yamakawa Y, et al. A single pretreatment with clofibric acid attenuates carbon tetrachloride-induced necrosis, but not steatosis, in rat liver. Food Chem Toxicol. 2020 Nov;145:111591. [Content Brief]

[7]. Forman BM, et, al. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4312-7. [Content Brief]

[8]. Salgado R, et, al. Biodegradation of clofibric acid and identification of its metabolites. J Hazard Mater. 2012 Nov 30;241-242:182-9. [Content Brief]

[9]. Kawashima Y, et, al. Increased activity of stearoyl-CoA desaturation in liver from rat fed clofibric acid. Biochim Biophys Acta. 1982 Dec 13;713(3):622-8. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	4.6587 mL	23.2937 mL	46.5875 mL	116.4687 mL
DMSO	5 mM	0.9317 mL	4.6587 mL	9.3175 mL	23.2937 mL
	10 mM	0.4659 mL	2.3294 mL	4.6587 mL	11.6469 mL
	15 mM	0.3106 mL	1.5529 mL	3.1058 mL	7.7646 mL
	20 mM	0.2329 mL	1.1647 mL	2.3294 mL	5.8234 mL
	25 mM	0.1863 mL	0.9317 mL	1.8635 mL	4.6587 mL
	30 mM	0.1553 mL	0.7765 mL	1.5529 mL	3.8823 mL
	40 mM	0.1165 mL	0.5823 mL	1.1647 mL	2.9117 mL
	50 mM	0.0932 mL	0.4659 mL	0.9317 mL	2.3294 mL
	60 mM	0.0776 mL	0.3882 mL	0.7765 mL	1.9411 mL
	80 mM	0.0582 mL	0.2912 mL	0.5823 mL	1.4559 mL
	100 mM	0.0466 mL	0.2329 mL	0.4659 mL	1.1647 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Clofibric acid

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Clofibric acid

Anti-Infection Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antibacterial Compound Library

Ubiquitination Compound Library

Anti-COVID-19 Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Nuclear Receptor Compound Library

E3 Ligase Ligand Library

Coagulation and Anti-coagulation Compound Library

Off-patent Drug Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Structurally Diverse Fragment Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Clofibric acid

Alle PPAR Isoform-spezifische Produkte anzeigen

Alle Ligands for E3 Ligase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Clofibric acid Related Classifications

HY-B1415 Related Classifications